Early access
Sign in
Taking people in NetherlandsPhase 4

Testing patiromer to help kidney disease patients take higher doses of RAAS blockers

Tests patiromer against placebo in adults with chronic kidney disease, stage 3b or 4.

Key facts

Who runs it
University Medical Center Groningen
Where
Amsterdam, Groningen, Leeuwarden, and Zwolle, NetherlandsSee the 4 sites
Registry title
PROMISE
Status
Recruiting
Phase
Phase 4
People taking part
44 people, planned
Started
16 May 2024
Expected to end
1 Oct 2027
Type of study
Interventional
Record updated
12 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic kidney disease stage 3b-4 who take an ACE inhibitor or ARB blood pressure medicine at less than the highest dose.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Chronic kidney disease stage 3b-4 (eGFR 15-44 mL/min/1.73 m2), with an albumin-creatinine ratio above 3 mg/mmol.
Earlier treatment
Must be taking an ACEi/ARB at a sub-maximal dose. Must not have had an ACEi/ARB dose cut in the last year because eGFR fell by more than 25%.
Biomarker or test result
Serum potassium (K+) 4.0-5.0 mmol/L. Systolic blood pressure above 130 mmHg, or taking one or more blood pressure drugs.

Main reasons for not taking part

  • ACEi/ARB dose cut in the last year because eGFR fell by more than 25%
  • Severe high potassium (above 6.0 mmol/L) in the last year
  • Pregnancy or breastfeeding
  • Life expectancy under 12 months

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age ≥ 18 years; CKD stage 3b-4 (eGFR 15-44 mL/min/1.73 m2 - Albumin-creatinine ratio >3 mg/mmol - Systolic blood pressure >130 mmHg or use of one or more antihypertensive drugs; Serum K+ 4.0-5.0 mmol/L; On sub-maximal dose ACEi/ARB

Who cannot take part

  • Prior ACEi/ARB dose reduction due to a drop in eGFR by >25% in the last year; history of severe hyperkalaemia (>6.0 mmol/L) in the last year; pregnancy or breastfeeding; life expectancy <12 months

Where in Netherlands

  • Amsterdam UMCAmsterdam, NetherlandsTaking people
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
  • Medisch Centrum Leeuwarden B.V.Leeuwarden, NetherlandsTaking people
  • Isala Klinieken StichtingZwolle, NetherlandsTaking people

About the trial

What the trial wants to find out

To demonstrate that patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with CKD stage 3b/4, resulting in a significant reduction in albuminuria.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
PROMISE: Potassium correction for RAAS Optimization in Chronic Kidney Disease
Plain-language title
Testing patiromer to help kidney disease patients take higher doses of RAAS blockersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 December 2025